BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fycompa (Perampanel) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fycompa (Perampanel)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04015141-1636@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Fycompa (Perampanel): Phase 2 readout est. (NCT04015141)
DESCRIPTION:Fycompa (Perampanel)\, phase 2\, Epilepsy.\nStudy: A Study to E
 valuate Efficacy and Safety of Perampanel Administered as an Adjunctive Th
 erapy in Pediatric Participants With Childhood Epilepsy\nEstimated primary
  completion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/perampanel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04015141
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06401707-1636@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Fycompa (Perampanel): Phase 2 readout est. (NCT06401707)
DESCRIPTION:Fycompa (Perampanel)\, phase 2\, Epilepsy.\nStudy: PeRampanel f
 Or Status ePilEpticus pRophylaxis Post-cardiac Arrest\nEstimated primary c
 ompletion: 20 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/perampanel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06401707
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284069-1636@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Fycompa (Perampanel): Phase 1 readout est. (NCT07284069)
DESCRIPTION:Fycompa (Perampanel)\, phase 1.\nStudy: Senicapoc and Perampane
 l for Newly Diagnosed Glioblastoma\nEstimated primary completion: 1 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/perampanel#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07284
 069
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05915013-1636@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Fycompa (Perampanel): Phase 1 readout est. (NCT05915013)
DESCRIPTION:Fycompa (Perampanel)\, phase 1.\nStudy: Alpha-Amino-3-Hydroxy-5
 -Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depres
 sant Ketamine Response\nEstimated primary completion: December 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/perampanel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05915013
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786066-1636@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Fycompa (Perampanel): Phase 2 readout est. (NCT05786066)
DESCRIPTION:Fycompa (Perampanel)\, phase 2.\nStudy: The Impact of AMPA Rece
 ptor Blockade on Ketamine's Anti-Suicidal Effects\nEstimated primary compl
 etion: March 2033. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 rampanel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05786066
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
